{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:27:31Z","timestamp":1789198051676,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015646","name":"OMRON Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejca.2023.113258","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T13:48:39Z","timestamp":1690465719000},"page":"113258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial"],"prefix":"10.1016","volume":"192","author":[{"given":"Karim","family":"Fizazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-8691","authenticated-orcid":false,"given":"G\u00fcnter","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egils","family":"Vjaters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1661-0853","authenticated-orcid":false,"given":"Toni","family":"Sarapohja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113258_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2018.07.035","article-title":"Managing nonmetastatic castration-resistant prostate cancer","volume":"75","author":"Mateo","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.113258_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41391-020-00310-3","article-title":"Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors","volume":"24","author":"Saad","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2023.113258_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113258_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jgo.2018.02.007","article-title":"Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers","volume":"9","author":"Ramsdale","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ejca.2023.113258_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2023.113258_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2021.09.036","article-title":"Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings","volume":"160","author":"Vogl","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113258_bib7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113258_bib8","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113258_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"7 suppl","key":"10.1016\/j.ejca.2023.113258_bib10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography [abstract]","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113258_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.2019.37.7_suppl.297","article-title":"Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: results from clinical and in vitro studies [abstract 297]","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113258_bib12","doi-asserted-by":"crossref","unstructured":"Williams S, Mazibuko N, O.'Daly O, Zurth C, Patrick F, Wooldridge C, et al. Significant localized reduction in cerebral blood flow in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers [poster]. Annual Genitourinary Cancers Symposium. San Francisco, CA; 2020.","DOI":"10.1200\/JCO.2020.38.6_suppl.326"},{"key":"10.1016\/j.ejca.2023.113258_bib13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","article-title":"Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer","volume":"16","author":"Fizazi","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.113258_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.07.018","article-title":"Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer stratified by prostate-specific antigen doubling time: planned subgroup analysis of the phase 3 ARAMIS trial","volume":"83","author":"B\u00f6gemann","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.113258_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2021.06.010","article-title":"Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase 3 ARAMIS trial","volume":"154","author":"Smith","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113258_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bju.15887","article-title":"Impact of darolutamide on local symptoms: preplanned and post hoc analyses of the ARAMIS trial","volume":"131","author":"Shore","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2023.113258_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcp.13425","article-title":"Drug\u2013drug interaction potential in men treated with enzalutamide: mind the gap","volume":"84","author":"Benoist","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2023.113258_bib18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/17425255.2021.2027908","article-title":"Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice","volume":"17","author":"Vicente-Valor","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejca.2023.113258_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-021-02183-0","article-title":"Polypharmacy and severe potential drug\u2013drug interactions among older adults with cardiovascular disease in the United States","volume":"21","author":"Sheikh-Taha","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.ejca.2023.113258_bib20","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1634\/theoncologist.2019-0406","article-title":"Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis","volume":"25","author":"Mohamed","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.113258_bib21","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113258_bib22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113258_bib23","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1158\/1078-0432.CCR-15-2638","article-title":"Phase Ib study of enzalutamide in combination with docetaxel in men with metastatic castration-resistant prostate cancer","volume":"22","author":"Morris","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113258_bib24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41391-021-00328-1","article-title":"Treating the patient and not just the cancer: therapeutic burden in prostate cancer","volume":"24","author":"Spratt","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2023.113258_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2023.113258_bib26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","article-title":"Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer","volume":"59","author":"Duran","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2023.113258_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/bdd.2103","article-title":"Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters","volume":"38","author":"Weiss","year":"2017","journal-title":"Biopharm Drug Dispos"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300360X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300360X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:12Z","timestamp":1760733732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300360X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"alternative-id":["S095980492300360X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113258","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113258"}}